HGF and metabolic dysfunction-associated steatohepatitis: Given that recombinant HGF has shown positive effects on reducing fibrosis in various animal disease models,23,24,25,30,32,33,40 we assessed the therapeutic capabilities of Fc(mML1)B3 in a mouse model exhibiting hepatic features of NASH.